ASX:CYPCynata Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Cynata Therapeutics Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add A$0.68 -0.02 (-2.86 %) (As of 05/13/2020) Add Compare Share Today's RangeA$0.68Now: A$0.68▼A$0.7150-Day RangeA$0.64MA: A$0.70▼A$0.8452-Week RangeA$0.58Now: A$0.68▼A$1.87Volume159,853 shsAverage VolumeN/AMarket Capitalization$70.05 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAdvanced ChartCompetitorsEarningsInsider TradesHeadlines Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes a proprietary mesenchymal stem cell technology under the Cymerus brand name for human therapeutic use in Australia. Its lead therapeutic product candidate is CYP-001, which is in Phase I clinical trial for the treatment of graft versus host disease. The company also develops products for the treatment of heart attack, asthma, acute respiratory distress syndrome, diabetic wounds, coronary artery disease, brain cancer, and critical limb ischaemia, which are in preclinical model. The company has a partnership with Monash University, Critical Care Research Group, University of Sydney, Department of Neurosurgery at Brigham and Women's Hospital - Harvard Medical School, the Cooperative Research Centre for Cell Therapy Manufacturing, University of New South Wales, and the Royal College of Surgeons Ireland to develop stem cell therapies. It also has a strategic partnership with Fujifilm Corporation of Japan for the development and research of Cymerus technology. The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013. Cynata Therapeutics Limited was founded in 2011 and is based in Carlton, Australia.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Cynata Therapeutics. Previous Next 2.7 Community Rank Outperform VotesCynata Therapeutics has received 16 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCynata Therapeutics has received 14 “underperform” votes. (Add your “underperform” vote.)Community SentimentCynata Therapeutics has received 53.33% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Cynata Therapeutics and other stocks. Vote “Outperform” if you believe CYP will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CYP will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCynata Therapeutics does not currently pay a dividend.Dividend GrowthCynata Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cynata Therapeutics insiders have not sold or bought any company stock. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cynata Therapeutics are expected to grow in the coming year, from A($0.11) to A$0.00 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cynata Therapeutics is -8.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cynata Therapeutics is -8.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCynata Therapeutics has a P/B Ratio of 7.16. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.67 out of 5 stars Industry, Sector and Symbol Stock Exchange ASX Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolASX:CYP Previous Symbol CUSIPN/A CIKN/A Webwww.cynata.com Phone61 3 9824 5254Debt Debt-to-Equity RatioN/A Current Ratio5.66 Quick Ratio5.42Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$4.45 million Price / Sales15.74 Cash FlowA$0.06 per share Price / Cash Flow11.93 Book ValueA$0.10 per share Price / Book7.16Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares103,018,000Market Cap$70.05 million Next Earnings DateN/A OptionableNot Optionable Receive CYP News and Ratings via Email Sign-up to receive the latest news and ratings for CYP and its competitors with MarketBeat's FREE daily newsletter. Cynata Therapeutics (ASX:CYP) Frequently Asked Questions How has Cynata Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Cynata Therapeutics' stock was trading at A$0.93 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CYP stock has decreased by 26.9% and is now trading at A$0.68. View which stocks have been most impacted by Coronavirus. How were Cynata Therapeutics' earnings last quarter? Cynata Therapeutics Ltd (ASX:CYP) posted its earnings results on Wednesday, February, 27th. The company reported ($0.03) EPS for the quarter, hitting the consensus estimate of ($0.03). View Cynata Therapeutics' earnings history. Has Cynata Therapeutics been receiving favorable news coverage? Media coverage about CYP stock has been trending very positive this week, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Cynata Therapeutics earned a media sentiment score of 3.5 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news aboutCynata Therapeutics. Who are some of Cynata Therapeutics' key competitors? Some companies that are related to Cynata Therapeutics include IMV (IMV), Emblem (EMC), Pfenex (PFNX), Novacyt (NCYT), Exicure (XCUR), Fennec Pharmaceuticals (FRX), Bioventix (BVXP), Theratechnologies (TH), Exicure (XCUR), Enochian Biosciences (ENOB), Antibe Therapeutics (ATE), Ergomed (ERGO), Rafael (RFL), Pfenex (PFNX) and OncoCyte (OCX). View all competitors. What other stocks do shareholders of Cynata Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cynata Therapeutics investors own include Starpharma (SPL), Mesoblast (MSB) and Immutep (IMM). Who are Cynata Therapeutics' key executives? Cynata Therapeutics' management team includes the following people: Dr. Ross Alexander MacDonald Ph.D., MD, CEO & Exec. Director (Age 61)Mr. Peter G. Webse B.Bus, FGIA, FCIS, FCPA, MAICD, Company Sec. & Non-Exec. Director (Age 56)Dr. Kilian Kelly, VP of Product Devel. What is Cynata Therapeutics' stock symbol? Cynata Therapeutics trades on the ASX under the ticker symbol "CYP." What is Cynata Therapeutics' stock price today? One share of CYP stock can currently be purchased for approximately A$0.68. How big of a company is Cynata Therapeutics? Cynata Therapeutics has a market capitalization of $70.05 million and generates $4.45 million in revenue each year. What is Cynata Therapeutics' official website? The official website for Cynata Therapeutics is www.cynata.com. How can I contact Cynata Therapeutics? The company can be reached via phone at 61 3 9824 5254. This page was last updated on 6/2/2020 by MarketBeat.com Staff
